Question: What are the benefits of consumer drug advertising from the patient standpoint?
Answer: It can stimulate the physician-patient relationship by encouraging patients to address certain health-care issues with their physicians. It could be a public health-care plus for individuals who are seeking care for undiagnosed illnesses. In some ways it can enhance the doctor-patient relationship, […]
Nonsteroidal anti-inflammatory drugs, or NSAIDS, are assumed to be well tolerated and are widely used as a therapy for common pain and conditions such as arthritis. These pharmaceuticals constitute one of the most widely used class of drugs, with more than 70 million prescriptions and more than 30 billion over-the-counter tablets sold annually in the […]
People who have survived a first heart attack have a higher risk of dying or having a second heart attack if they are taking non-steroidal anti-inflammatory drugs (NSAIDs), including the newer class called cox-2 inhibitors.
The research detailing these findings appears in the June 20 issue of the journal Circulation, and was first presented at the […]
According to an article recently published in Clinical Cancer Research , the addition of Celebrex® (celecoxib) to Tarceva® (erlotinib) appears to significantly improve anticancer responses compared to Tarceva alone in advanced lung cancer. Longer follow-up is necessary to determine how these response rates will ultimately affect patient outcomes.
Lung cancer remains the leading cause of death […]
It’s safe to assume that most people don’t have sex on the brain in a hospital emergency room.
That might explain why the Viagra ad in the ER area at the Montreal General Hospital once caused a bit of a fuss.
“It wasn’t the ad itself,” said Francoise Chagnon, director of professional services at the McGill University […]
The first trial over claims that Pfizer Inc.’s painkiller Celebrex causes strokes, set to start today in an Alabama state court, was postponed to give lawyers more time to gather information about the drug.
A federal judge in San Francisco, where Pfizer faces more than 1,500 lawsuits over its Celebrex and Bextra painkillers, requested the […]
NEW YORK, May 19 — Celebrex (celecoxib), the Cox-2 inhibitor, increases blood pressure compared with placebo, but the rise is not as great as it is among patients taking Advil (ibuprofen), Aleve (naproxen), or other nonselective NSAIDs.
“Numerically, [Celebrex] is somewhere in the middle between placebo, which doesn’t raise blood pressure at all, and nonselective […]
May 19, 2006 (New York City) — The popular antiarthritis drug Celebrex appears to raise blood pressure, but the effect is not as large as that associated with the use of some other painkillers such as Advil or Aleve, according to a study of over 44,000 people.
“HypertensionHypertension was more prevalent in patients given Celebrex […]
Review
LOS ANGELES, June 1 — Celebrex (celecoxib), the Cox-2 inhibitor, and Tarceva (erlotinib), the epidermal growth factor-receptor (EGFR) inhibitor, have been teamed with some preliminary success to inhibit late-stage non-small-cell lung cancer.
Over-expression of Cox-2 in tumor cells was seen in preclinical studies to cause resistance to drugs like Tarceva, which block tumor cell growth […]